Drug Trial Radar · NCT06667544
A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation
Last checked: Nov 19, 2026Latest source record: Oct 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
152
Planned (sponsor's estimate)
Start
Nov 8, 2024
Primary completion
Dec 2026
Study completion Jul 2027
Sponsor
- Lead sponsor
- Ranok Therapeutics (Hangzhou) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 31, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first in human (FIH), Phase 1/2 open-label multi-center, dose escalation and expansion study to evaluate the safety, tolerability and pharmacokinetics of RNK08954 to determine the optimal dose and recommended dose for expansion and evaluate clinical activity in patients with advanced solid tumors with KRAS G12D mutation. This is a 2-part study: dose exploration/indication expansion and dose optimization ( to identify a dose that preserves clinical benefit with optimal tolerability).
Conditions
- KRAS G12D Mutation
Interventions
RNK08954-01Drug
Once daily oral treatment for a 3 week cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent adverse events (TEAEs).Time frame: 12-15 months
- Optimal Biological Dose (OBD).Time frame: 12-15 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China · Recruiting
Shanghai Chest Hospital
Shanghai, China · Recruiting
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.